Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBITDA (2016 - 2025)

Perspective Therapeutics' EBITDA history spans 16 years, with the latest figure at -$25.9 million for Q3 2025.

  • For Q3 2025, EBITDA fell 38.77% year-over-year to -$25.9 million; the TTM value through Sep 2025 reached -$110.4 million, down 91.83%, while the annual FY2024 figure was -$90.9 million, 121.99% down from the prior year.
  • EBITDA for Q3 2025 was -$25.9 million at Perspective Therapeutics, down from -$21.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $299000.0 in Q4 2021 and bottomed at -$45.0 million in Q4 2024.
  • The 5-year median for EBITDA is -$9.8 million (2023), against an average of -$11.4 million.
  • The largest annual shift saw EBITDA surged 134.25% in 2021 before it crashed 1979.93% in 2022.
  • A 5-year view of EBITDA shows it stood at $299000.0 in 2021, then plummeted by 1979.93% to -$5.6 million in 2022, then tumbled by 107.72% to -$11.7 million in 2023, then crashed by 285.27% to -$45.0 million in 2024, then skyrocketed by 42.52% to -$25.9 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's EBITDA are -$25.9 million (Q3 2025), -$21.5 million (Q2 2025), and -$18.1 million (Q1 2025).